Purpose: The Cell Cycle Progression (CCP) score has been associated with prostate cancer outcome in various clinical settings. However, previous studies of men treated by radical prostatectomy (RP) evaluated CCP scores generated from resected tumor tissue. Here we evaluated the prognostic utility of the score derived from biopsy specimens in men who were treated by radical prostatectomy.
| Click HERE to read a related article |
Methods: We evaluated the CCP score in patient cohorts from the Martini Clinic (MC) (N=283), from the Durham VA Medical Center (DVA) (N=176), and from Intermountain Healthcare (IHC) (N=123). The CCP score was derived from simulated biopsy (MC) or diagnostic biopsy (DVA and IHC) and evaluated for association with biochemical recurrence (BCR) and metastatic disease.
Results: In all three cohorts, the CCP score was associated with BCR and metastatic disease. The association with BCR remained significant after adjusting for other prognostic clinical variables. In a combined analysis of all cohorts (N=582), the CCP score was a strong predictor of BCR in both univariable (HR/unit score=1.60 (95%CI: 1.35, 1.90; p-value=2.4x10-7)) and multivariable analyses (HR/unit score=1.47 (95%CI: 1.23, 1.76; p-value=4.7x10-5)). Although there were few events (N=12), CCP score was the strongest predictor of metastatic disease in both univariable analysis (HR/unit score=5.35 (95%CI: 2.89, 9.92; p-value=2.1x10-8)), and after adjusting for clinical variables (HR/unit score=4.19 (95%CI: 2.08, 8.45; p-value=8.2x10-6)).
Conclusion: CCP score derived from a biopsy sample was associated with adverse outcome after surgery. These results indicate that the CCP score can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.
Written by:
Bishoff JT, Freedland SJ, Gerber L, Tennstedt P, Reid J, Welbourn W, Graefen M, Sangale Z, Tikishvili E, Park J, Younus A, Gutin A, Lanchbury JS, Sauter G, Brawer M, Stone S, Schlomm T Are you the author?
Intermountain Healthcare, Salt Lake City, UT. Electronic address: . 2Department of Surgery, Durham VA Medical Center; Department of Surgery (Urology) and Pathology, Duke University School of Medicine, Durham, NC. 3Department of Surgery, Durham VA Medical Center; Department of Surgery (Urology), Duke University School of Medicine, Durham, NC. 4Martini-Clinic, Prostate Cancer Center, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 5Myriad Genetics, Inc., Salt Lake City, UT. 6Institute for Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Reference: J Urol. 2014 Feb 6. (Epub ahead of print)
doi: 10.1016/j.juro.2014.02.003
PubMed Abstract
PMID:24508632
